[go: up one dir, main page]

WO2010133941A3 - Nouvelles particules hybrides et utilisations de celles-ci pour des diagnostics et à des fins thérapeutiques - Google Patents

Nouvelles particules hybrides et utilisations de celles-ci pour des diagnostics et à des fins thérapeutiques Download PDF

Info

Publication number
WO2010133941A3
WO2010133941A3 PCT/IB2010/001145 IB2010001145W WO2010133941A3 WO 2010133941 A3 WO2010133941 A3 WO 2010133941A3 IB 2010001145 W IB2010001145 W IB 2010001145W WO 2010133941 A3 WO2010133941 A3 WO 2010133941A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnostics
therapy
hybrid particles
new hybrid
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2010/001145
Other languages
English (en)
Other versions
WO2010133941A2 (fr
Inventor
Loredana Latterini
Fausto Elisei
Luigi Tarpani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita degli Studi di Perugia
Original Assignee
Universita degli Studi di Perugia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita degli Studi di Perugia filed Critical Universita degli Studi di Perugia
Publication of WO2010133941A2 publication Critical patent/WO2010133941A2/fr
Publication of WO2010133941A3 publication Critical patent/WO2010133941A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0026—Acridine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Ceramic Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des nouvelles particules pouvant être utilisées pour diagnostiquer et pour traiter certaines pathologies Plus particulièrement, l'invention concerne des nanoparticules destinées à être utilisées pour le diagnostic et le traitement de tumeurs, ainsi que des compositions contenant ces particules.
PCT/IB2010/001145 2009-05-20 2010-05-17 Nouvelles particules hybrides et utilisations de celles-ci pour des diagnostics et à des fins thérapeutiques Ceased WO2010133941A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2009A000887A IT1394302B1 (it) 2009-05-20 2009-05-20 "nuove particelle ibride e loro uso in diagnosi e terapia"
ITMI2009A000887 2009-05-20

Publications (2)

Publication Number Publication Date
WO2010133941A2 WO2010133941A2 (fr) 2010-11-25
WO2010133941A3 true WO2010133941A3 (fr) 2011-01-13

Family

ID=41506422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/001145 Ceased WO2010133941A2 (fr) 2009-05-20 2010-05-17 Nouvelles particules hybrides et utilisations de celles-ci pour des diagnostics et à des fins thérapeutiques

Country Status (2)

Country Link
IT (1) IT1394302B1 (fr)
WO (1) WO2010133941A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025513A2 (fr) * 2003-09-12 2005-03-24 The Regents Of The Univeristy Of California Derives de guanidinium pour l'amelioration du transfert cellulaire
WO2006102307A2 (fr) * 2005-03-21 2006-09-28 University Of Louisville Research Foundation, Inc. Nanoparticules specifiques d'une cible destinees a ameliorer le contraste optique et a induire l'hyperthermie specifique de la cible
WO2008140624A2 (fr) * 2006-12-22 2008-11-20 The Board Of Regents Of The University Of Texas System Méthodes et compositions associées à des nanoparticules hybrides
WO2009032752A2 (fr) * 2007-08-28 2009-03-12 University Of Florida Research Foundation, Inc. Nanoparticules multimodales destinées à une bio-imagerie non invasive

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025513A2 (fr) * 2003-09-12 2005-03-24 The Regents Of The Univeristy Of California Derives de guanidinium pour l'amelioration du transfert cellulaire
WO2006102307A2 (fr) * 2005-03-21 2006-09-28 University Of Louisville Research Foundation, Inc. Nanoparticules specifiques d'une cible destinees a ameliorer le contraste optique et a induire l'hyperthermie specifique de la cible
WO2008140624A2 (fr) * 2006-12-22 2008-11-20 The Board Of Regents Of The University Of Texas System Méthodes et compositions associées à des nanoparticules hybrides
WO2009032752A2 (fr) * 2007-08-28 2009-03-12 University Of Florida Research Foundation, Inc. Nanoparticules multimodales destinées à une bio-imagerie non invasive

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KANDPAL D. ET AL.: "Synthesis and characterization of silica-gold core-shell (SiO2@Au) nanoparticles.", PRAMANA -J. PHYS., vol. 69, no. 2, 1 August 2007 (2007-08-01), pages 277 - 283, XP007911186 *
LEOPOLD K ET AL.: "Gold-Coated Silica as a preconcentration phase for the determination of total dissolved mercury in natural waters using atomic fluorescence spectrometry", ANAL CHEM., vol. 81, no. 9, 1 May 2009 (2009-05-01), XP007911176 *

Also Published As

Publication number Publication date
IT1394302B1 (it) 2012-06-06
ITMI20090887A1 (it) 2010-11-21
WO2010133941A2 (fr) 2010-11-25

Similar Documents

Publication Publication Date Title
IL261338B (en) Preparations and methods for the treatment of wide-ranging, undifferentiated or mixed clinical applications
HK1202877A1 (en) Anti-cd98 antibodies and methods of use thereof
MX2011007930A (es) Conjugados de insulina cristalina.
IL220974A0 (en) Compositions and methods for the diagnosis and treatment of tumor
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
EP4324527A3 (fr) Formulations d'enzalutamide
PL2544698T3 (pl) Kompozycja zawierająca bakterie probiotyczne do zastosowania w leczeniu zaburzeń odporności
WO2010099161A8 (fr) Microarn chez les non-fumeurs et méthodes et matières apparentées
IL237649B (en) Polymer meters drug for use in the prevention, diagnosis and/or treatment of diseases of the joint
PH12014500903A1 (en) Bispecific immunobinders directed against tnf and il-17
WO2010083385A3 (fr) Composés permettant de réduire la résistance aux médicaments et leurs utilisations
HK1202313A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
IL240560A0 (en) Preparations and methods for tumor diagnosis and treatment
HK1206393A1 (en) Compositions and methods for diagnosis and treatment of pervasive developmental disorder
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
IL234101B (en) Preparations containing acamprosate and baclofen for use in the treatment of Parkinson's disease
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
WO2014205266A3 (fr) Compositions et méthodes pour la détection et le traitement du glioblastome
WO2013106747A3 (fr) Méthodes et compositions pour le traitement et le diagnostic du cancer de la thyroïde
MX2013011231A (es) Nanoparticulas basadas en lipidos.
PL2276498T3 (pl) Zastosowanie bakterii probiotycznych do leczenia hiperhomocysteinemii
HK1215391A1 (zh) 使用胎盘细胞外基质治疗口腔病变
WO2011029052A3 (fr) Nanoparticules de carbone primaire
SG194235A1 (en) Methods of predicting the development of complement-mediated disease
WO2011047011A3 (fr) Traitement et diagnostic des troubles inflammatoires

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10730507

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10730507

Country of ref document: EP

Kind code of ref document: A2